Ivax receives expanded approval for cancer drug

April 2004
PharmaWatch: Cancer;April 2004, Vol. 3 Issue 4, p18
Market Research Report
Focuses on the European Commission's expanded approval of Paxene, Ivax Corp.'s injectable form of the cancer drug paclitaxel, to cover the treatment of metastatic breast cancer and metastic ovarian cancer. Ivax's deal with Mayne Group Ltd. concerning marketing and distribution of Paxene in Europe.


Related Articles

  • Ivax gains recommendation in Europe for injectable paclitaxel anticancer drug.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p18 

    Reports on the European Medicines Evaluation Agency's recommendation of the extension of the marketing authorization for Ivax Corp.'s proprietary injectable Paclitaxel to include the treatment of metastatic breast cancer and metastatic ovarian cancer. Identification of Paclitaxel as the active...

  • A Phase I/II Study of Lapatinib Plus Carboplatin and Paclitaxel in Relapsed Ovarian and Breast Cancer. Rivkin, Saul E.; Muller, Carolyn; Malmgren, Judith A.; Moon, James; Iriarte, Desiree; Arthur, Jane; Gerould, Heather // Clinical Ovarian Cancer;Nov2009, Vol. 2 Issue 2, p112 

    Purpose: Our objective was to find the maximum tolerated combination dose of daily oral lapatinib and weekly carboplatin (C) and paclitaxel (T; metronomic mCT). The secondary objectives included toxicity, safety, and efficacy of response to therapy in patients with relapsed ovarian and breast...

  • paclitaxel. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p580 

    An encyclopedia entry for "paclitaxel" is presented. It refers to an anticancer drug used for the treatment of several cancers like ovarian cancer and breast cancer. It outlines some of the side effects of paclitaxel, including nausea, vomiting, anaemia and increased susceptibility to infection.

  • paclitaxel.  // Royal Society of Medicine: Medicines;2002, p421 

    The article presents information on paclitaxel, a cytotoxic drug, the first of a new group of drugs termed the taxanes. It is used as an anticancer drug in the treatment of ovarian and breast cancer, and also non-small cell lung cancer. Administration is by intravenous infusion.

  • Phase III Randomized Trial of Docetaxel—Carboplatin Versus Paclitaxel—Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. Vasey, Paul A.; Jayson, Gordon C.; Gordon, Alan; Gabra, Hani; Coleman, Rob; Atkinson, Ronnie; Parkin, David; Paul, James; Hay, Andrea; Kaye, Stan B. // JNCI: Journal of the National Cancer Institute;11/17/2004, Vol. 96 Issue 22, p1682 

    Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard of care for treatment of ovarian carcinoma. We compared the combination of docetaxel-carboplatin with the combination of paclitaxel-carboplatin as first-line chemotherapy for stage Ic-IV...

  • Design and characterization of anionic PEGylated liposomal formulation loaded with paclitax for ovarian cancer. Makwana, K.; Tandel, H. // Journal of Pharmacy & Bioallied Sciences;Mar2012 Supplement, pS17 

    Despite its strong antitumor activity, paclitaxel (Taxol®) has limited clinical applications due to its low aqueous solubility and hypersensitivity caused by cremophor EL and ethanol which is the vehicle used in the current commercial product. In an attempt to develop a pharmaceutically...

  • Sequential therapy warranted where combo therapy inappropriated.  // PharmacoEconomics & Outcomes News;1/28/2006, Issue 495, p6 

    Discusses research being done on sequential drug therapy with capecitabine. Reference to study being done by N. Reynoso et al, which appeared in the 2005 issue of the journal "Breast Cancer Research and Treatment"; Cost effectiveness of sequential therapy with capecitabine followed by either...

  • Synthesis and antiproliferative and c-Src kinase inhibitory activities of cinnamoyl- and pyranochromen-2-one derivatives. Chand, Karam; Shirazi, Amir Nasrolahi; Yadav, Preeti; Tiwari, Rakesh K.; Kumari, Meena; Parang, Keykavous; Sharma, Sunil K. // Canadian Journal of Chemistry;Aug2013, Vol. 91 Issue 8, p741 

    A series of 6- and 8-cinnamoylchromen-2-one and dihydropyranochromen-2-one derivatives were synthesized and their antiproliferative activities were evaluated against three human cancer cell lines, i.e., ovarian adenocarcinoma (SK-OV-3), leukemia (CCRF-CEM), and breast carcinoma (MCF-7). In...

  • taxanes. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p731 

    An encyclopedia entry for "taxanes" is presented. It refers to a group of anticancer drugs used for the treatment of certain cancers such as ovarian cancer and breast cancer. These drugs work by preventing the development of cancer cells. The drugs, paclitaxel and docetaxel are the two common...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics